ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Belharra Therapeutics has emerged from stealth with $50 million in series A funding from Versant Ventures and an $80 million multiyear collaboration deal with Genentech. With a founding team that includes Benjamin Cravatt of Scripps Research in California and Stuart Schreiber of the Broad Institute of MIT and Harvard, Belharra aims to screen for noncovalent small-molecule drugs with its chemical probe technology, which the company touts as working for any protein binding site in any cell type.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X